Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Vorinostat in Combination With Vincristine, Irinotecan, and Temozolomide in Children, Adolescents, and Young Adults With Relapsed or Refractory Solid Tumors and CNS Malignancies

NCT04308330 is registered in ClinicalTrials.gov with New York Medical College as lead sponsor.

NCT NCT04308330
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04308330 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Vorinostat in Combination With Vincristine, Irinotecan, and Temozolomide in Children, Adolescents, and Young Adults With Relapsed or Refractory Solid Tumors and CNS Malignancies
Lead sponsor
New York Medical College
Phase
Phase 1
Overall status
Recruiting
Start date
March 17, 2017
Completion date
December 31, 2027
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ewing sarcoma, germ cell tumor, hepatoblastoma, neuroblastoma, rhabdomyosarcoma, wilms tumor